Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProPILARifax: Rifaximin for SBP Prophylaxis in Cirrhosis
NCT03069131Phase 3Completed
- Sponsor
- CHU de Besançon
- Start
- Jun 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in spontaneous bacterial peritonitis (SBP) comparing Active rifaximin with Rifaximin placebo (2 arms). Primary endpoint: Death at 12 months. Started Jun 2018; status: completed.
02
Drugs
rifaximin
03
Conditions
spontaneous bacterial peritonitis (SBP)
Beyond the preview
Go deeper on NCT03069131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03069131.